Rubius Therapeutics, Inc. (RUBY) Financial Statements (2024 and earlier)
Company Profile
| Business Address |
C/O VERDOLINO & LOWEY, P.C. FOXBORO, MA 02035 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2836 - Biological Products, Except Diagnostic Substances (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
| 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | |||
|---|---|---|---|---|---|---|---|
| ASSETS | |||||||
| Current Assets | |||||||
| Cash, cash equivalents, and short-term investments | 225,848 | 176,287 | 283,287 | 404,051 | |||
| Cash and cash equivalents | 225,848 | 91,165 | 91,898 | 307,064 | |||
| Short-term investments | 85,122 | 191,389 | 96,987 | ||||
| Restricted cash and investments | 100 | 100 | 622 | ||||
| Disposal group, including discontinued operation | |||||||
| Other undisclosed current assets | 3,875 | 5,124 | 5,979 | 9,737 | |||
| Total current assets: | 229,823 | 181,511 | 289,266 | 414,410 | |||
| Noncurrent Assets | |||||||
| Operating lease, right-of-use asset | 35,095 | 40,447 | 46,559 | ✕ | |||
| Property, plant and equipment | 51,530 | 53,952 | 56,924 | 62,796 | |||
| Restricted cash and investments | 1,573 | 1,573 | 1,735 | 1,735 | |||
| Other noncurrent assets | 311 | 357 | 168 | ||||
| Total noncurrent assets: | 88,198 | 96,283 | 105,575 | 64,699 | |||
| TOTAL ASSETS: | 318,021 | 277,794 | 394,841 | 479,109 | |||
| LIABILITIES AND EQUITY | |||||||
| Liabilities | |||||||
| Current Liabilities | |||||||
| Accounts payable and accrued liabilities | 21,347 | 14,564 | 12,758 | 7,886 | |||
| Interest and dividends payable | ✕ | 1,654 | 408 | 213 | |||
| Employee-related liabilities | ✕ | 7,451 | 8,124 | 5,045 | |||
| Accounts payable | 11,572 | 5,478 | 7,178 | 7,886 | |||
| Accrued liabilities | 670 | 554 | 322 | ||||
| Debt | 10,540 | ||||||
| Other undisclosed current liabilities | 13,312 | 13,276 | 10,462 | 12,118 | |||
| Total current liabilities: | 34,659 | 27,840 | 33,760 | 20,004 | |||
| Noncurrent Liabilities | |||||||
| Long-term debt and lease obligation | 104,445 | 107,706 | 86,463 | 65,788 | |||
| Long-term debt, excluding current maturities | 76,154 | 74,944 | 49,596 | 24,347 | |||
| Capital lease obligations | ✕ | ✕ | ✕ | ✕ | 41,441 | ||
| Liabilities, other than long-term debt | 135 | 688 | 405 | 143 | |||
| Deferred rent credit | 143 | ||||||
| Other liabilities | 135 | 688 | 405 | ||||
| Operating lease, liability | 28,291 | 32,762 | 36,867 | ✕ | |||
| Other undisclosed noncurrent liabilities | 166 | ||||||
| Total noncurrent liabilities: | 104,580 | 108,394 | 86,868 | 66,097 | |||
| Total liabilities: | 139,239 | 136,234 | 120,628 | 86,101 | |||
| Equity | |||||||
| Equity, attributable to parent | 178,782 | 141,560 | 274,213 | 393,008 | |||
| Common stock | 90 | 81 | 80 | 79 | |||
| Additional paid in capital | 855,710 | 621,946 | 586,798 | 543,040 | |||
| Accumulated other comprehensive income (loss) | 4 | 75 | (29) | ||||
| Accumulated deficit | (677,018) | (480,471) | (312,740) | (150,082) | |||
| Total equity: | 178,782 | 141,560 | 274,213 | 393,008 | |||
| TOTAL LIABILITIES AND EQUITY: | 318,021 | 277,794 | 394,841 | 479,109 | |||
Income Statement (P&L) ($ in thousands)
| 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | ||
|---|---|---|---|---|---|---|
| Revenues (Sublease Income) | 719 | 1,017 | 908 | |||
| Gross profit: | 719 | 1,017 | 908 | |||
| Operating expenses | (194,616) | (166,448) | (169,601) | (91,663) | ||
| Other undisclosed operating loss | (719) | (1,017) | (908) | |||
| Operating loss: | (194,616) | (166,448) | (169,601) | (91,663) | ||
| Nonoperating income (expense) | (1,931) | (1,283) | 6,143 | 2,468 | ||
| Investment income, nonoperating | 91 | 1,760 | 7,994 | 329 | ||
| Other nonoperating income | 4,412 | 1,142 | 739 | |||
| Interest and debt expense | (6,434) | (4,185) | (2,590) | (464) | ||
| Loss from continuing operations: | (202,981) | (171,916) | (166,048) | (89,659) | ||
| Loss before gain (loss) on sale of properties: | ✕ | (202,981) | (171,916) | (166,048) | (89,659) | |
| Other undisclosed net income (loss) | 6,434 | 4,185 | 2,590 | 464 | ||
| Net loss available to common stockholders, diluted: | (196,547) | (167,731) | (163,458) | (89,195) | ||
Comprehensive Income ($ in thousands)
| 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | ||
|---|---|---|---|---|---|---|
| Net loss: | (196,547) | (167,731) | (163,458) | (89,195) | ||
| Comprehensive loss: | (196,547) | (167,731) | (163,458) | (89,195) | ||
| Other undisclosed comprehensive income (loss), net of tax, attributable to parent | (4) | (71) | 104 | (29) | ||
| Comprehensive loss, net of tax, attributable to parent: | (196,551) | (167,802) | (163,354) | (89,224) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.